Written and medically reviewed by Dr Zeeshan Afzal (MBBS) — Medical Doctor & Medical Content Lead, Welzo
Evidence-based · Honest about what's proven and what isn't · UK-focused
Last updated: July 2026 · Reading time: ~12 minutes
The oestrobolome — spelled estrobolome in American sources — is the collection of gut bacterial genes capable of metabolising oestrogen. It has become one of the most enthusiastically marketed ideas in women's health, usually attached to something you can buy. The underlying biology is real and genuinely interesting. The claims built on top of it frequently run well ahead of the evidence. This guide separates the two. For the wider science see our digestive health hub, and the practical options in the Welzo gut health supplement range.
Table of contents
The term was coined in 2011 by Claudia Plottel and Martin Blaser in Cell Host & Microbe, who defined it as the aggregate of enteric bacterial genes whose products are capable of metabolising oestrogens. It is not a specific organ, organism or test result — it is a functional capacity distributed across many different species in your gut.
Oestrogen produced by the ovaries, adrenal glands and fat tissue is processed in the liver, where it is conjugated — bound to glucuronic acid or sulfate — which switches off its biological activity and marks it for excretion. Bacteria carrying GUS genes produce β-glucuronidase, which strips that tag off in the intestine, restoring the oestrogen to its active form (Gut Microbes review, 2023). Reactivated oestrogen can then be reabsorbed rather than excreted.
Most consumer content stops at β-glucuronidase. Researchers increasingly do not. Bacterial sulfatase may matter as much or more, since it converts oestrone sulfate — the body's largest circulating oestrogen reservoir — back into active oestrone and oestradiol (Current Opinion in Endocrine and Metabolic Research, 2026). Any product claiming to target "the oestrobolome" by addressing one enzyme is oversimplifying a system we do not yet fully understand.
The quantities involved explain why researchers took this seriously. Up to 65% of circulating oestrogens are excreted into the gut in bile, but only 10–15% are eliminated in faeces — meaning the large majority is reabsorbed rather than lost.
| Stage | What happens | Why it matters |
|---|---|---|
| 1. Production | Ovaries, adrenals and adipose tissue produce oestrogens | Body fat is itself a source, via aromatase |
| 2. Inactivation | Liver conjugates oestrogen, switching it off | Liver function and bile flow are part of the picture |
| 3. Excretion into gut | Conjugated oestrogen enters the intestine in bile | Roughly 65% of circulating oestrogens take this route |
| 4. Reactivation | Bacterial β-glucuronidase and sulfatase deconjugate it | This is the oestrobolome's actual job |
| 5. Reabsorption or exit | Reactivated oestrogen re-enters circulation; the rest leaves in stool | Only 10–15% is eliminated — fibre and transit affect this |
This is enterohepatic recirculation, the same principle that governs bile acids. It is also why constipation is mechanistically relevant: material that sits in the colon longer has more opportunity to be deconjugated and reabsorbed.
This is the section most articles skip, and it is where the honest picture lives.
Flores and colleagues studied 29 people (7 postmenopausal women and 22 men) and found gut microbiome richness and diversity were strongly positively related to urinary oestrogens, while faecal β-glucuronidase activity correlated positively with urinary oestrone and inversely with faecal total oestrogens — consistent with microbial recycling. Notably, these associations were not seen in the 19 premenopausal women studied.
Fuhrman and colleagues then reported that postmenopausal women with more diverse gut microbiomes showed a higher ratio of hydroxylated oestrogen metabolites to parent oestrogens (J Clin Endocrinol Metab, 2014). More recently, a 2026 PNAS analysis of 24 populations across four continents found industrialised populations had up to seven times greater oestrogen-recycling capacity and nearly twofold higher oestrobolome diversity than non-industrial groups — a striking finding whose health implications are not yet worked out.
Three caveats deserve equal billing with the findings above.
The reasonable position: oestrogen recycling through the gut is real, its magnitude is meaningful, and its clinical controllability is unproven.
This is where the evidence is most developed, partly because the oestrogen decline is so pronounced. Population data has found postmenopausal women show decreased abundance of microbial β-glucuronidase and higher abundance of microbial sulfate transport systems, with these functions correlating with serum hormone metabolites. Causality runs in both directions — falling oestrogen alters the microbiome, and the altered microbiome recycles less oestrogen. See gut health in menopause and gut health and ageing.
PCOS gets folded into oestrobolome marketing, but the gut link here is mostly about insulin, not oestrogen recycling. Elevated insulin drives ovarian androgen production and suppresses sex hormone-binding globulin, leaving more free testosterone in circulation. Anything that improves insulin sensitivity is therefore mechanistically relevant — which is why gut health and blood sugar matters more here than β-glucuronidase does.
Berberine is the most-studied supplement in this space. A meta-analysis of nine randomised trials in PCOS with insulin resistance concluded it showed a promising prospect but that data were insufficient for firm conclusions, finding no significant difference versus metformin. A broader umbrella meta-analysis found berberine improved fasting glucose, HbA1c, HOMA-IR and inflammatory markers across type 2 diabetes and PCOS, while cautioning about high heterogeneity between studies. Berberine is not a NICE-recommended PCOS treatment, interacts with a long list of medicines, and is unsuitable in pregnancy or breastfeeding — see berberine interactions and berberine vs metformin, and speak to your GP before starting it.
Both are oestrogen-dependent, which makes the oestrobolome a plausible modifier, and altered gut microbiomes have been reported in endometriosis. But as noted above, the enzyme data has not supported the simple version of the hypothesis, and no gut-directed intervention has been shown to treat either condition. Endometriosis requires proper gynaecological management.
Because lifetime oestrogen exposure influences risk of hormone-receptor-positive breast cancer, the oestrobolome has been studied as a possible contributor, and differences in bacterial GUS enzymes between healthy women and breast cancer patients have been described. This remains hypothesis-generating. Nothing here establishes that altering your microbiome changes cancer risk, and no supplement should be presented as prevention. Attend your NHS breast screening invitations and report any breast change to your GP.
The classic study remains instructive. Goldin and colleagues compared vegetarian and omnivorous premenopausal women in the New England Journal of Medicine: vegetarians ate more fibre (28g versus 12g daily), and showed higher faecal oestrogen excretion, significantly reduced faecal bacterial β-glucuronidase activity, and plasma oestrone and oestradiol that correlated negatively with faecal oestrogen excretion. A later intervention trial found increasing dietary fibre reduced serum oestrogen concentrations in premenopausal women.
Fibre works through two routes at once: it lowers β-glucuronidase activity, and it binds oestrogen in the intestine to increase faecal excretion. Practical guidance: 30 plants a week, high-fibre foods in the UK, and how to increase fibre without triggering bloating.
If oestrogen leaves the body in stool, how efficiently stool leaves matters. Chronic constipation extends the window for deconjugation and reabsorption. This is unglamorous but more actionable than any oestrobolome test — see the Bristol stool chart and magnesium for constipation.
Soy isoflavones illustrate the oestrobolome concept better than almost anything else. Daidzein from soy is converted by specific gut bacteria into equol, a more biologically active compound — but only some people carry the bacteria to do it, with equol production notably more common in Asian than Western populations. Two people can eat identical soy and produce different metabolites. That is a genuine, demonstrated example of microbial hormone metabolism differing between individuals.
Adipose tissue produces oestrogen via aromatase, so body composition directly affects circulating levels — see gut health and weight loss. Alcohol raises circulating oestrogen and burdens the liver's conjugation capacity. Antibiotics and other long-term medicines reshape the microbial enzymes involved, which is one reason long-term medication use is now being studied specifically for its effect on oestrobolome activity. Never stop prescribed medication without medical advice.
Fermentable fibre also produces short-chain fatty acids, which lower colonic pH — itself relevant to bacterial enzyme activity — and support gut barrier function. Supporting microbiome diversity and avoiding dysbiosis is sensible general practice, not a hormone treatment.
"Oestrogen detox," "hormone balance" and "oestrobolome reset" products are a large and largely unregulated category. Here is my honest read.
| Approach | Evidence for hormone outcomes | Verdict |
|---|---|---|
| Dietary fibre | Human intervention and comparative data | Best-supported; start here |
| Treating constipation | Mechanistically sound; worth doing regardless | Sensible and low-risk |
| Probiotics | No strain shown to reliably alter oestrogen levels in humans | Reasonable for gut symptoms, not for hormones |
| Berberine | Trials in PCOS insulin resistance; promising, heterogeneous | Discuss with GP; many interactions |
| DIM / I3C | Alters urinary metabolite ratios; clinical benefit unproven | Marketed far ahead of evidence |
| Calcium-D-glucarate | Largely preclinical, on β-glucuronidase inhibition | Insufficient human data |
| TUDCA | Bile-acid signalling; not a hormone intervention | Judge on its own merits |
For general gut support, see the best probiotics in the UK, probiotics for women and probiotics safety. On bile pathways specifically, TUDCA vs milk thistle covers what is and is not known.
Not meaningfully, and this is worth being blunt about. Some private stool tests report β-glucuronidase activity, and urinary hormone metabolite panels report oestrogen metabolite ratios. Neither has a validated reference range for oestrobolome function, neither predicts clinical outcomes, and no intervention has been shown to improve outcomes when guided by them. Our gut microbiome test guide sets out what these tests can and cannot do.
If you have hormonal symptoms, standard clinical assessment — history, examination and, where indicated, validated blood tests through your GP — remains far more useful than a microbiome report.
See your GP promptly if you have:
Do not attempt to self-manage these with supplements. See also when to see a GP about stomach symptoms. Source: NHS — Postmenopausal bleeding.
The oestrobolome (estrobolome in US spelling) is the collection of gut bacterial genes whose enzymes can metabolise oestrogen. The term was coined in 2011. It describes a functional capacity spread across many bacterial species rather than a specific organism, organ or measurable test result.
The liver inactivates oestrogen and excretes it into the gut in bile. Bacterial enzymes — chiefly β-glucuronidase, and probably sulfatase too — reactivate it, allowing reabsorption into the bloodstream instead of excretion. Around 65% of circulating oestrogens enter the gut this way, yet only 10–15% leave in stool.
A bacterial enzyme that removes the glucuronic acid tag the liver attaches to oestrogen, restoring its biological activity. Higher activity has been associated with more oestrogen recycling in small human studies, though it is not the only enzyme involved and its clinical significance is not fully established.
Not in the way that phrase implies. Fibre intake and bowel transit genuinely influence how much oestrogen is excreted versus reabsorbed, and those are worth optimising. But no gut intervention has been shown to reliably correct a hormonal disorder, and "balancing hormones" is a marketing phrase rather than a clinical outcome.
The human evidence points that way. Comparative work found women eating substantially more fibre excreted more oestrogen in stool, had lower faecal β-glucuronidase activity, and showed plasma oestrogen levels that correlated inversely with faecal excretion. An intervention trial found increased fibre reduced serum oestrogen in premenopausal women.
There is no probiotic strain currently shown to reliably alter oestrogen levels in humans. Probiotics have a legitimate evidence base for certain digestive outcomes, and improving gut symptoms may well make you feel better, but they should not be bought as hormone treatments.
It has been studied as a possible contributor, because lifetime oestrogen exposure affects risk of hormone-receptor-positive breast cancer, and differences in bacterial enzymes have been described between healthy women and breast cancer patients. This is hypothesis-generating research. No supplement or microbiome intervention has been shown to reduce breast cancer risk — attend your screening invitations.
Yes, and the relationship appears bidirectional. Population data has found postmenopausal women show reduced microbial β-glucuronidase abundance alongside other functional shifts. Falling oestrogen alters the microbiome, and the altered microbiome recycles less oestrogen — which makes untangling cause from effect difficult.
Not usefully. Some private tests report faecal β-glucuronidase activity or urinary oestrogen metabolite ratios, but there is no validated reference range, no demonstrated link between results and outcomes, and no intervention proven to work when guided by them.
It is mechanistically plausible, since slower transit gives bacteria longer to reactivate conjugated oestrogen before it can be excreted, and older work linked bowel transit to hormone levels. Regardless of the hormonal question, persistent constipation is worth addressing on its own terms — and any lasting change in bowel habit should be discussed with your GP.
Medical disclaimer: This article is for general information and education only and does not constitute medical advice, diagnosis or treatment. It should not replace consultation with a qualified healthcare professional. Always seek advice from your GP or a suitably qualified clinician about hormonal, gynaecological or digestive symptoms, and before starting new supplements — particularly if you are pregnant, trying to conceive, breastfeeding, taking hormonal contraception or HRT, or on any medication. Berberine is unsuitable in pregnancy and breastfeeding and interacts with many medicines. Never stop prescribed medication without medical advice. Any postmenopausal bleeding needs prompt medical assessment.
About the author
Dr Zeeshan Afzal (MBBS) is a practising medical doctor and Welzo's Medical Content Lead. He writes and reviews Welzo's health content to ensure it is accurate, evidence-based and aligned with current UK clinical guidance, translating complex research into practical advice patients can trust.
Évalué Excellent par 26,523+ avis
Garantie de remboursement à 100%
Notre garantie de rétroaction garantit que vous recevez vos articles ou obtenez un remboursement complet.
